Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Novus Medical Detox Center Calls for Regulators to Support New Anti-Abuse Technologies
  • USA - English


News provided by

JoTo PR

Dec 05, 2016, 08:00 ET

Share this article

Share toX

Share this article

Share toX

Bryn Wesch, CFO of Novus Medical Detox Center, urges regulators to back anti-abuse technologies
Bryn Wesch, CFO of Novus Medical Detox Center, urges regulators to back anti-abuse technologies

There is no single, simple solution to the U.S. opioid crisis, which has been years in the making. However, new anti-abuse technologies are one way to help prevent diversion and misuse.

Post this

NEW PORT RICHEY, Fla., (PRWEB) December 05, 2016 -- The U.S. societal costs of opioid misuse, dependence and abuse were estimated to be $55.7 billion as of 2007;(1) and given that opioid overdose deaths have climbed over 31% since then,(2) those costs have continued to rise. Novus Medical Detox Center, a leading Florida-based drug treatment facility, believes technological innovations show promise in helping to deter opioid abuse. However, Novus emphasizes that regulations and policies must promote those anti-abuse technologies in conjunction with education and drug treatment programs to ensure optimal outcomes.

The U.S. Food and Drug Administration (FDA) has already approved seven opioid formulations with abuse-deterrent properties, and others are currently in development or awaiting approval.(3) Advanced technologies make the new pills difficult to crush or create a gooey consistency when crushed, which deters users from inhaling or injecting the drugs for a faster, more intense high. Other abuse-deterrent formulations combine opioids with naloxone or naltrexone, which blocks the effects of opioids if the pills are crushed rather than orally administered.(3)

Some experts have expressed concern that government regulations often hinder the adoption of these types of anti-abuse technologies. For example, newer tamper-resistant drugs may be excluded from state Medicaid formularies, while lengthy FDA review and approval processes may delay the rollout of promising new innovations.(4)

“There is no single, simple solution to the U.S. opioid crisis, which has been years in the making. However, new anti-abuse technologies are one way to help prevent diversion and misuse,” explained Bryn Wesch, CFO of Novus Medical Detox Center. “Federal and state regulations should be continually assessed and updated to ensure they promote access to the most effective and innovative treatments, and FDA processes should be analyzed and accelerated where possible.”

At the same time, Wesch stresses that abuse-deterrent and tamper-resistant formulations should not be misconstrued as abuse-proof, since orally ingesting excessive quantities of the medications can still result in overdoses and other adverse effects. Even “bridge drugs” intended to help users overcome opioid addiction—including buprenorphine/naloxone combinations such as Suboxone—are subject to diversion and can lead to dependency.

“Beyond promoting new technologies and expediting FDA reviews, government agencies should focus on educating the public of the risks associated with prescription opioids, supporting research and development of non-opioid alternatives, and expanding access to detox and drug rehab programs,” asserted Wesch. “This type of multi-pronged approach is the best way to prevent the growing trend of opioid misuse and abuse while helping those with opioid use disorders achieve a successful long-term recovery.”

Finally, Wesch advocates for better use of an existing but currently underutilized technology: prescription drug monitoring programs (PDMPs). She believes regulators should require all healthcare professionals to consult PDMP data before issuing an opioid prescription, which can help identify potential cases of abuse or diversion. Wesch would also like to see expanded PDMP interoperability between states, so physicians and pharmacists can get a complete picture of all medications prescribed to a patient, regardless of where they obtained or filled the prescription.

Novus offers medically supervised detox programs, including customized treatment plans designed to minimize the discomfort of opioid withdrawal. The Florida drug detox facility provides individualized care based on proven medical protocols, with 24-hour access to nursing staff and withdrawal specialists. Novus is renowned for its expertise in treating high-dose methadone cases, and is proficient in detoxing patients from other high-dose opioids and “bridge drugs” just as safely, comfortably and effectively.

For more information on Novus Medical Detox Center and its opioid treatment programs, visit http://www.novusdetox.com.

About Novus Medical Detox Center:
Novus Medical Detox Center has earned The Joint Commission’s Gold Seal of Approval for Behavioral Health Care Accreditation as an inpatient medical detox facility. Licensed by the Florida Department of Children and Families, Novus provides safe, effective alcohol and drug treatment programs that are based on proven medical protocols and designed to minimize the discomfort of withdrawal. The facility is located on 3.25 acres in New Port Richey, Florida, in a tranquil, spa-like setting bordering protected conservation land. Intent on proving that detox doesn’t have to be painful or degrading, Novus set out to transform the industry by bringing humanity into medical detox with individually customized treatment programs and 24/7 access to nursing care and withdrawal specialists. Today, Novus is renowned as a champion of industry standardization and a staunch advocate of patients fighting to overcome substance use disorders. Frequently recognized for its contributions to the industry and local community, Novus has become a regular source to media publications such as The Wall Street Journal and USA Today, and has ranked in the Tampa Bay Business Journal’s Fast 50, the Florida Business Journal’s Top 500 and the Inc. 5000 list of America’s fastest-growing companies. For more information on Novus’ medically supervised detox programs, visit http://novusdetox.com.

1. Birnbaum, Howard G.; Alan G. White; et al. “Societal Costs of Prescription Opioid Abuse, Dependence, and Misuse in the United States”; Pain Medicine; April 2011. painmedicine.oxfordjournals.org/content/12/4/657.long

2. CDC/NCHS. “Number and Age-Adjusted Rates of Drug-Poisoning Deaths Involving Opioid Analgesics and Heroin: United States, 2000–2014”; National Vital Statistics System, Mortality File; December 9, 2015. cdc.gov/nchs/data/health_policy/AADR_drug_poisoning_involving_OA_Heroin_US_2000-2014.pdf

3. Throckmorton, Dr. Douglas C. “Key Facts About ‘Abuse-Deterrent’ Opioids”; blog post on FDA website; October 28, 2016. blogs.fda.gov/fdavoice/index.php/2016/10/key-facts-about-abuse-deterrent-opioids/

4. Winegarden, Wayne for EconoSTATS. “Regulations Should Promote Innovative Opioid Abuse Technologies”; Forbes; November 14, 2016. forbes.com/sites/econostats/2016/11/14/regulations-should-promote-innovative-opioid-abuse-technologies/#29474b224750

Karla Jo Helms, JoTo PR, +1 (888) 202-4614 Ext: 802, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.